RC48 Combined With Tislelizumab

DRUG2 trials

Sponsors

RenJi Hospital

Conditions

HER-2 ADCKidney PreservationPD-1antibodyUpper Tract Urothelial CarcinomaUpper Urinary Tract Urothelial Carcinoma

Phase 2

Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients

RecruitingNCT05912816

RenJi HospitalHER-2 ADC, Kidney Preservation, PD-1antibody +1

Start: 2023-06-10End: 2026-12-30Target: 20Updated: 2025-12-09

Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma

Not yet recruitingNCT07584733

RenJi HospitalUpper Tract Urothelial Carcinoma

Start: 2026-05-31End: 2028-12-31Target: 50Updated: 2026-05-13